OBI Pharma
Manufacturing · Taiwan · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Nankang Software Park 19f Park St 3-2, T...Phone Number
(619) 537-7698Website
www.obipharma.comRevenue
$9.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About OBI Pharma
OBI Pharma is a clinical-stage global oncology company focused on developing novel therapeutic agents, particularly antibody-drug conjugates (ADCs), for patients with unmet medical needs. The company operates with a strong emphasis on research and development, showcasing advanced technologies and a robust pipeline of innovative cancer therapies. OBI Pharma aims to expand its reach internationally while maintaining a commitment to employee well-being and sustainability. Their intended clients include healthcare providers and patients seeking cutting-edge cancer treatments.Explore more
OBI Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OBI Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
OBI Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when OBI Pharma launches new products
Website visits: Recent activity has been detected on your website
Check out if OBI Pharma is spiking on competitors!
Click to see if OBI Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at OBI Pharma
Funding: Get notified immidiatlly once OBI Pharma has new funding data
Earning: See what the market has to say on OBI Pharma recently announced quarterly report
Check if OBI Pharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to OBI Pharma
Compare insights from companies similar to OBI Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OBI Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OBI Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OBI Pharma.
OBI Pharma Tech Stack
A closer look at the technologies used by OBI Pharma
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Product Marketing, Events, Training, Sales, Learning & Development, Doctors / Physicians, Medical Education & Training, Field /Outside Sales, Field Marketing
OBI Pharma News & Media
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
TAIPEI, TW, Jan 12, 2026 - (ACN Newswire) - OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receiveOBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
TAIPEI, TAIWAN, Nov 17, 2025 - (ACN Newswire) - OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the UniteOBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology for evaluation of safety and efficacy in Cancer. OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology for evaluation of safety and efficacy in Cancer.OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services Agreement (MSA).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OBI Pharma
Sign Up For FreeTo access detailed company insights
OBI Pharma is a clinical-stage global oncology company focused on developing novel therapeutic agents, particularly antibody-drug conjugates (ADCs), for patients with unmet medical needs. The company operates with a strong emphasis on research and development, showcasing advanced technologies and a robust pipeline of innovative cancer therapies. OB... Read More
